TITLE

Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin allergy

AUTHOR(S)
Pappalardo, F.; Franco, A.; G., G. Crescenzi; Poli, A.; Zangrillo, A.; Koster, A.
PUB. DATE
January 2007
SOURCE
Perfusion;Jan2007, Vol. 22 Issue 1, p67
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Heparin-induced IgE-mediated hypersensitivity and anaphylactoid reactions, although rare, can pose a serious clinical problem for patients requiring cardiopulmonary bypass (CPB). Bivalirudin is a bivalent reversible direct thrombin inhibitor, with a half-life of 25 min, eliminated mostly by proteolytic cleavage. There are some reports on the use of bivalirudin for cardiac surgery, particularly for heparin-induced thrombocytopenia (HIT), but none on cases of heparin allergy. We report a case of heparin allergy successfully managed for CPB with bivalirudin anticoagulation.
ACCESSION #
25545899

 

Related Articles

  • Heparin.  // Reactions Weekly;4/1/2006, Issue 1095, p12 

    Presents a case report involving heparin-induced thrombocytopenia following heart surgery. Reference to a study conducted by I. Husedrisov, N. Bradic, N. Nikic, S. Barisin and M. Desmica published in the February 2006 issue of "Anaesthesia and Intensive Care"; Decrease in the platelet count of...

  • Comparison of ACT point-of-care measurements: repeatability and agreement. Bosch, Y. P. J.; Ganushchak, Y. M.; de Jong, D. S. // Perfusion;Jan2006, Vol. 21 Issue 1, p27 

    Background: Accurate control of heparin anticoagulation is necessary during all stages of cardiopulmonary bypass (CPB). The activated clotting time, first described by Hattersley in 1966, is mostly used for determination of anticoagulation. Either celite or kaolin are used as activators. An ACT...

  • Thrombocytopenia Associated with Antithrombotic Therapy in Patients with Cardiovascular Diseases: Diagnosis and Treatment. Kilickiran Avci, Burcak; Oto, Ali; Ozcebe, Osman // American Journal of Cardiovascular Drugs;2008, Vol. 8 Issue 5, p327 

    Agents with antiplatelet and anticoagulant activity have been proved to be effective in reducing the incidence of complications following acute coronary syndrome, percutaneous coronary intervention, and cardiopulmonary bypass. However, these agents, including heparin, glycoprotein IIb/IIIa...

  • Effects of protective and conventional mechanical ventilation on pulmonary function and systemic cytokine release after cardiopulmonary bypass. Koner, Ozge; Celebi, Serdar; Balci, Huriye; Cetin, Gurkan; Karaoglu, Kamil; Cakar, Nahit // Intensive Care Medicine;Apr2004, Vol. 30 Issue 4, p620 

    Objective: To evaluate the effects of protective and conventional ventilation with or without positive end-expiratory pressure (PEEP), on systemic tumor necrosis factor-alpha, interleukin-6 levels and pulmonary function during open heart surgery.Design: Prospective,...

  • cardiopulmonary bypass. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p145 

    An encyclopedia entry for "cardiopulmonary bypass" is presented. It refers to a procedure commonly used during heart surgery by which the circulation of blood around the body is maintained while the heart is stopped during surgery. To maintain the supply of oxygenated blood to the body tissues,...

  • Lepirudin as an alternative to "heparin allergy" during cardiopulmonary bypass. Parissis, Haralabos // Journal of Cardiothoracic Surgery;2011, Vol. 6 Issue 1, p44 

    A treatment strategy of a difficult and unusual problem is presented. We are reporting a case of a patient who had a documented allergy to heparin and required Cardiac surgery for an ASD closure. The anticoagulation regime used during cardiopulmonary bypass was lepirudin based. This report...

  • Aprotinin protects the cerebral microcirculation during cardiopulmonary bypass. Ishibashi, N.; Iwata, Y.; Zurakowski, D.; Lidov, H. G. W.; Jonas, R. A. // Perfusion;Mar2009, Vol. 24 Issue 2, p99 

    Background and objective: We have previously reported that administration of aprotinin at a single dose protects the cerebral microcirculation. The current study was designed to identify the optimal dose for protecting the cerebral microcirculation with assessment of neurological and behavioral...

  • Management of coagulation during cardiopulmonary bypass. O'Carroll-Kuehn, Britta U.; Meeran, Hanif // Continuing Education in Anaesthesia, Critical Care & Pain;Dec2007, Vol. 7 Issue 6, p195 

    The article presents information on the management of coagulation during cardiopulmonary bypass. It states that coagulation and inflammatory pathways occur by contact of the blood with the cardiopulmonary bypass (CPB) circuit and surgical wound during open heart surgery. The mechanism of action...

  • Emerging Technologies in Biocompatible Surface Modifying Additives: Quest for Physiologic Cardiopulmonary Bypass. Gunaydin, Serdar // Current Medicinal Chemistry - Cardiovascular & Hematological Age;Oct2004, Vol. 2 Issue 4, p295 

    Modification of polymer surfaces to achieve a surface with enhanced compatibility is an important means of obtaining improved biomaterials. The molecular design of the novel technologies is carried out with attention to create a biomembrane-mimicking surface on medical devices. This review...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics